During the last session, Chemours Company (NYSE:CC)’s traded shares were 1.37 million, with the beta value of the company hitting 1.98. At the end of the trading day, the stock’s price was $26.65, reflecting an intraday loss of -0.71% or -$0.19. The 52-week high for the CC share is $39.05, that puts it down -46.53 from that peak though still a striking 43.34% gain since the share price plummeted to a 52-week low of $15.10. The company’s market capitalization is $3.96B, and the average intraday trading volume over the past 10 days was 2.84 million shares, and the average trade volume was 1.89 million shares over the past three months.
Chemours Company (NYSE:CC) trade information
Chemours Company (CC) registered a -0.71% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.71% in intraday trading to $26.65, hitting a weekly high. The stock’s 5-day price performance is 5.09%, and it has moved by -12.59% in 30 days. Based on these gigs, the overall price performance for the year is -14.28%. The short interest in Chemours Company (NYSE:CC) is 4.71 million shares and it means that shorts have 2.01 day(s) to cover.
Chemours Company (CC) estimates and forecasts
Statistics show that Chemours Company has underperformed its competitors in share price, compared to the industry in which it operates. Chemours Company (CC) shares have gone down -15.53% during the last six months, with a year-to-date growth rate less than the industry average at -36.27% against 2.20. In the rating firms’ projections, revenue will decrease -11.70% compared to the previous financial year.
Revenue for the current quarter is expected to be $1.32 billion as predicted by 5 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to $1.55 billion by the end of Mar 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $1.34 billion and $1.46 billion respectively. In this case, analysts expect current quarter sales to shrink by -1.60% and then jump by 5.90% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -1.34%. While earnings are projected to return -35.01% in 2024, the next five years will return 7.40% per annum.
CC Dividends
Chemours Company is due to release its next quarterly earnings between April 25 and April 29. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Chemours Company is 1.00, with the dividend yield indicating at 3.75 percent, continuing the trend of increasing dividends in recent years.
Chemours Company (NYSE:CC)’s Major holders
Chemours Company insiders own 0.78% of total outstanding shares while institutional holders control 77.54%, with the float percentage being 78.15%. FMR, LLC is the largest shareholder of the company, while 578 institutions own stock in it. As of Jun 29, 2023, the company held over 18.92 million shares (or 12.78% of all shares), a total value of $697.98 million in shares.
The next largest institutional holding, with 17.05 million shares, is of Blackrock Inc.’s that is approximately 11.52% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $629.16 million.
Also, the Mutual Funds coming in first place with the largest holdings of Chemours Company (CC) shares are Vanguard Total Stock Market Index Fund and iShares Core S&P Midcap ETF. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 4.63 million shares. This amounts to just over 3.13 percent of the company’s overall shares, with a $170.8 million market value. The same data shows that the other fund manager holds slightly less at 4.63 million, or about 3.13% of the stock, which is worth about $129.84 million.
